Raymond James Remains a Hold on Aerie Pharma (AERI)

In a report released today, Elliot Wilbur from Raymond James maintained a Hold rating on Aerie Pharma (AERIResearch Report). The company’s shares closed last Monday at $9.92.

According to TipRanks.com, Wilbur is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -3.0% and a 41.7% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Amneal Pharmaceuticals, and Flexion Therapeutics.

Aerie Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $24.25.

See today’s analyst top recommended stocks >>

The company has a one-year high of $26.26 and a one-year low of $10.22. Currently, Aerie Pharma has an average volume of 663.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.